Kirkland, Washington-based Cardiac Dimensions develops minimally invasive treatments for heart failure with functional mitral regurgitation (FMR). That includes the Carillon Mitral Contour System, for which the company has the ongoing EMPOWER trial. Its new CMO served as an advisor on that trial.
“I’ve seen the compelling clinical evidence on Carillon therapy from Europe and look forward to helping the team expand the supportive body of evidence for this intriguing technology with the U.S. pivotal EMPOWER trial,” said Shreenivas. “I have always been energized by my work with emerging technologies that fill an unmet clinical need and am excited by the opportunity this therapy presents to enhance the lives of heart failure patients in a way that isn’t possible today.”
More about the new CMO at Cardiac Dimensions
Shreenivas, a renowned interventional cardiologist, offers experience in both the clinical and commercial areas of structural heart. He led the structural heart program and cardiac catheterization laboratory at the University of Cincinnati. Additionally, he spent several years with the Christ Hospital in Ohio.
While at Christ Hospital, he served as an investigator in high-profile clinical trials, including structural heart studies. He has been widely published in peer-reviewed journals for work in structural heart, heart failure and coronary.
Shreenivas’ industry experience includes the CMO role at HLT Medical, a transcatheter heart valve company. He also served as chief of cardiology with Optum/United Health subsidiary SCA Health. Additionally, Shreenivas held the post of medical director for Medpace, a clinical research organization.
“We are thrilled to welcome Dr. Shreenivas to Cardiac Dimensions and expect his valuable combination of clinical and industry experience, passion for evidence generation, and innovative spirit will benefit the EMPOWER trial studying our Carillon device as a therapy for heart failure patients with functional mitral regurgitation,” said Cardiac Dimensions CEO Rick Wypych. “Having a structural heart leader like Satya as a member of the Cardiac Dimensions team will provide us with unique insights for our clinical research, as well as ongoing commercial efforts.”
